Several biological agents have been approved for the treatment of recalcitrant psoriasis. However, there is a lack of a consensus algorithm guiding the drug selection for patients who have failed conventional drugs. In cases not improving with cyclosporine, direct switching to a biological therapy usually leads to a disease flare owing to increased production of interleukin (IL)-17A. Thus, secukinumab, a rapidly acting anti-IL-17A drug, may be ideal in such situations.
SmithCHAnsteyAVBarkerJN, et al.British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol2005; 153: 486–497.
2.
MenterAKormanNJElmetsCA, et al.Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol2011; 65: 137–174.
3.
ColomboMDCassanoNBelliaG, et al.Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. Scientific World Journal2013; 2013: 805705.
4.
GanzettiGCampanatiABernardiniML, et al.The transitioning from conventional therapy to biological treatment in psoriatic patients: STRATOS, a project of Marche Region. G Ital Dermatol Venereol2016; 151: 340–346.
5.
MrowietzUKragballeKNastA, et al.Strategies for improving the quality of care in psoriasis with the use of treatment goals – a report on an implementation meeting. J Eur Acad Dermatol Venereol2011; 25: 1–13.
6.
ToriiHNakagawaH. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol2011; 38: 321–334.
7.
SaitohKKonSNakatsuruT, et al.Anti-IL-17A blocking antibody reduces cyclosporin A-induced relapse in experimental autoimmune encephalomyelitis mice. Biochem Biophy Rep2016; 8: 139–145.
8.
OhtsukiMMoritaAIgarashiA, et al.Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch. J Dermatol2017; 44: 1105–1111.
9.
KammüllerMTsaiTFGriffithsCE, et al.Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunology2017; 6: e152.
10.
NorlinJMSteen CarlssonKPerssonU, et al.Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice. Dermatology2012; 225: 326–332.
11.
Saitoh K, Kon S, Nakatsuru T et al. Anti-IL-17A blocking antibody reduces cyclosporin A-induced relapse in experimental autoimmune encephalomyelitis mice. Biochem Biophy Rep 2016; 8: 139–145.
12.
MrowietzUde JongEMKragballeK, et al.A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol2014; 28: 438–453.
